Skip to main content

Table 3 VEGF through the study period

From: Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals

HCV group VEGF1 VEGF2 VEGF3
Values (median (Q1–Q3)) 173.4 (146.6–199.3) 42.2 (31.3–78.3) 44.1 (31.8–55.3)
P value < 0.001
Post hoc  
 VEGF1–VEGF2 < 0.001
 VEGF1–VEGF3 < 0.001
 VEGF2–VEGF3 0.09
  1. VEGF1 measured at the end of treatment, VEGF2 measured one month after the end of treatment, and VEGF3 measured 3 months after the end of treatment